Kala Pharmaceuticals, Inc. (NASDAQ:KALA) (“Kala” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 50 pre-split shares. The reverse stock split will become effective at 4:05 p.m. on Thursday, October 20, 2022. Kala’s common stock will continue to be traded on the Nasdaq Global Select Market under the symbol KALA and will begin trading on a split-adjusted basis when the market opens on Friday, October 21, 2022. The new CUSIP number for the Company’s common stock following the reverse stock split will be 483119202.
Eldorado Gold Q2 EPS $0.08 Misses $0.13 Estimate
Eldorado Gold (NYSE:EGO) reported quarterly earnings of $0.08 per share which missed the analyst consensus estimate of $0.13 by 38.46 percent. This is a 50 percent decrease over earnings of $0.16 per share from the same
